Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Way Crossover, Pharmacokinetic Study to Evaluate the Relative Bioavailability of AB521 Tablet and Capsule Formulations and the Effect of Food on the Pharmacokinetics of the Tablet Formulation in Healthy Adult Volunteers

Next Previous
Search
Trial Profile

A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Way Crossover, Pharmacokinetic Study to Evaluate the Relative Bioavailability of AB521 Tablet and Capsule Formulations and the Effect of Food on the Pharmacokinetics of the Tablet Formulation in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Casdatifan (Primary) ; Casdatifan
  • Indications Cancer; Liver cancer; Renal cell carcinoma; Solid tumours
  • Focus Pharmacokinetics
  • Acronyms ARC-28
  • Sponsors Arcus Biosciences

    • Most Recent Events

    • 25 Oct 2024 Results evaluating pharmacokinetics profile of AB521 presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
    • 30 Oct 2023 Status changed from recruiting to completed.
    • 12 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top